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ABSTRACT: Glycogen synthase kinase-3 (GSK3), particularly the iso-
form GSK3b, has been implicated in a wide range of physiological sys-
tems and neurological disorders including Alzheimer’s Disease.
However, the functional importance of GSK3a has been largely
untested. The multifunctionality of GSK3 limits its potential as a drug
target because of inevitable side effects. Due to its greater expression in
the CNS, GSK3b rather than GSK3a has also been assumed to be of pri-
mary importance in synaptic plasticity. Here, we investigate bidirec-
tional long-term synaptic plasticity in knockin mice with a point
mutation in GSK3a or GSK3b that prevents their inhibitory regulation.
We report that only the mutation in GSK3a affects long-term potentia-
tion (LTP) and depression (LTD). This stresses the importance of investi-
gating isoform specificity for GSK3 in all systems and suggests that
GSK3a should be investigated as a drug target in cognitive disorders
including Alzheimer’s Disease. VC 2014 The Authors. Hippocampus Published
by Wiley Periodicals, Inc.
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INTRODUCTION
GSK3 is a highly conserved, multifunctional serine/threonine kinase;
particularly abundant in the hippocampus (Grimes and Jope, 2001).
Two isoforms of GSK3 are encoded by distinct genes, alpha and beta
(Woodgett, 1990) and assumed to have similar function (Asuni et al.,
2006). However, the isoform-specific actions are
poorly understood. GSK3 is active under basal condi-
tions but can be inhibited by N-terminal phosphoryl-
ation of Ser21 in GSK3a and Ser9 in GSK3b
(Rubio-Moscardo et al., 2013). Many types of pro-
teins are phosphorylated by GSK3 (Jope and Johnson,
2004) involving it in many intracellular pathways
(Rayasam et al., 2009) and this, together with its
prominent neuronal expression, leads GSK3 to be
implicated in various neurological disorders including
Alzheimer’s Disease (Cohen and Goedert, 2004;
Hernandez et al., 2009). Recent research has conse-
quently focussed on its role in synaptic plasticity
(Giese, 2009).
Consistent with a role in memory dysfunction, pre-
vious studies (Hooper et al., 2008; Peineau et al.,
2008) indicate that GSK3:
 inhibits long-term potentiation (LTP) when over-
expressed;
 prevents long-term depression (LTD) but not LTP
when inhibited and
 is inhibited by LTP and activated by LTD.
Most authors have assumed this pivotal role to
depend on GSK3b (Peineau et al., 2008), despite
using general GSK3 inhibitors which cannot differen-
tiate the functions of the GSK3 isoforms (Cohen and
Goedert, 2004; Georgievska et al., 2013). Other stud-
ies have attempted to be more specific by using over-
or under-expression models of GSK3b (Kimura et al.,
2008; Kaidanovich-Beilin and Woodgett, 2011). How-
ever, nonphysiological levels of GSK3 may have vari-
ous unforeseen knock-on effects, especially between
the isoforms. Distinct cellular localisation of GSK3a
has been demonstrated, which would be consistent
with functions independent of the b isoform (Azou-
lay-Alfaguter et al., 2011). Yet, most previous studies
have largely ignored the potential role of GSK3a, per-
haps because its expression levels are lower than
GSK3b and decrease with age (Giese, 2009).
One study demonstrated convincingly that GSK3b
was the dominant isoform in heart and skeletal muscle
(Mora et al., 2005) by developing GSK3 knockin mice
(KIs) in which the inhibitory serine residue of the
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respective isoform is mutated to alanine, thereby creating two KI
lines that lack the inhibitory regulation of either GSK3a or
GSK3b (McManus et al., 2005). Both lines have normal expres-
sion of both GSK3 isoforms, but the activity-dependent inactiva-
tion of the relevant isoform is disrupted allowing differentiation
of isoform-specific functions. To address the relative roles of the
two isoforms in synaptic plasticity, we have compared basal syn-
aptic transmission as well as LTP and LTD in hippocampal slices
from these same KI mice, using wild-type (WT) litter mates as
controls. Homozygous KI and WT littermates were kept
together with heterozygous littermates so that mice used in
experiments were never single housed. The genotype of all mice
used for experimentation was confirmed by post hoc analysis of
tail tissue using standard PCR techniques as previously described
(McManus et al., 2005). As LTD is difficult to induce in older
mice (Milner et al., 2004), two age groups of male KI and WT
mice were used in these experiments: 16- to 21-day-old for LTD
and 4- to 5-month-old for LTP.
Hippocampal brain slices were prepared using standard pro-
cedures modified for mice (Parsley et al., 2007) and left to
recover for at least half an hour before stimulating the Schaffer
collaterals and recording in the stratum radiatum of the CA1
field of hippocampal slices to obtain pairs of field excitatory
postsynaptic potentials (fEPSPs). Once a field response was
obtained, standard paired-pulse stimuli (stimulus duration: 100
ms, interstimulus interval: 50 ms) were applied at 0.1 Hz and
averaged over 1 min across a range of voltages (10–60 V) to
produce an input–output relationship. Thereafter, the stimulus
intensity of evoked fEPSPs was set to 50% of the voltage
required to evoke postsynaptic action potentials (“population
spike”) and paired-pulse stimuli were applied at 0.1 Hz and
averaged over 1 min. fEPSPs baseline was recorded for at least
15 min or until a stable response was obtained using standard
paired-pulse stimuli and the final 10 min taken for analysis.
The slope of averaged fEPSPs was determined with WinWCP
v.4.1.5 using a linear curve fitting function and data transferred
to SPSS 21.0 (IL) for statistical analysis using generalized linear
mixed models, which have fewer test-specific assumptions and
are more robust than standard analysis of variance (Krueger
and Tian, 2004). As there were no statistical differences in the
response of the respective WT litter mates of the two KI mice,
all data from WTmice were pooled in the analyses.
The input/output ratio was unaffected by genotype at either
of the ages studied (Figs. 1A,B) but GSK3aKIs showed signifi-
cantly lower paired-pulse ratios (PPR) than the other genotypes
at both ages (Figs. 1C,D) suggesting an increase in release
probability in GSK3aKIs compared with WTmice.
To induce LTP, a modified version of an established tetanus
protocol (Emptage et al., 2001) consisting of a series of 5 tetani
(100 Hz for 1s; 1.5s intertetanus interval) was applied to the
Schaffer collaterals. This resulted in robust LTP in GSK3bKIs
and WT slices (Fig. 2). In contrast, GSK3aKIs did not show
FIGURE 1. Basal synaptic transmission. (a) I/O curve; 19–21
days; WT: data from 32(12) slices(animals); GSK3aKI: 11(5);
GSK3bKI: 33(8). No significant difference by genotype. (b) I/O
curve; 4–6 months; WT: 17(9), GSK3aKI: 7(6), GSK3bKI: 15(6).
No significant difference by genotype. Symbols on I/O curves are
offset for purpose of visualisation but all genotypes were recorded
at the same voltages as indicated on the axis below. (c) PPR(50
ms); 19–21 days. Significant difference between genotypes
[F(2,73)5 6.5, P5 0.002]; post hoc comparison (adjusted using
Sidak correction) indicated lower PPR in GSK3aKI than WT or
GSK3bKI mice. (d) PPR(50 ms); 4–6 months. Significant differ-
ence between genotypes [F(2,37)5 7.6, P5 0.002]; post hoc com-
parison indicated lower PPR in GSK3aKI than WT or GSK3bKI
mice. **P< 0.01; *P< 0.05. (Data expressed as mean6 SEM).
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significant potentiation and this was significantly different from
the other genotypes (Fig. 2 inset). There was no change in PPR
between baseline and the last 10 min of recording in any of the
genotypes. Moreover, there was no significant difference in maxi-
mum level of post-tetanic potentiation nor its time course, sug-
gesting that the difference in LTP was not due to the difference
in basal release probability of the GSK3aKIs.
Robust LTD was induced following an established protocol
(Milner et al., 2004) of low-frequency stimulation (900 single
pulses at 1Hz) in slices from GSK3bKIs, which was indistin-
guishable from WT experiments (Fig. 3). Again, GSK3aKIs
were significantly different from the other genotypes, failing to
show depression (Fig. 3 inset).
Thus, contrary to previous assumptions, a mutation limiting
the dynamic range of GSK3b not only has no effect on basal
synaptic transmission but also affects neither LTP nor LTD. In
contrast, preventing inhibition of GSK3a prevents induction
of plasticity in either direction. Although it is clear that neither
direction of plasticity can be induced when inactivation of
GSK3a is prevented, it would be premature to conclude that
inactivation of GSK3a would be essential for induction of
both LTP and LTD in a wild type mouse. While we can be
confident that the mutation of GSK3b is ineffective in pre-
venting either form of plasticity, caution is necessary as to
whether the GSK3a mutation really affects both LTP and LTD
directly. Previous studies inhibiting both isoforms of GSK3
(Peineau et al., 2007; Bradley et al., 2012), would suggest that
preventing inactivation of the effective isoform could enhance
LTD while inhibiting LTP. Under these conditions synapses
would tend to become increasingly depressed in response to
activity. Hence, GSK3aKI mice, in which GSK3a cannot be
inhibited throughout life, may reach a floor effect where their
synapses cannot be any further depressed. This would be
entirely compatible with the observations here. Under such
conditions, induction of LTP would be inhibited because
GSK3a could not be inactivated while LTD would not be
induced because the synapses were already depressed as a result.
Moreover, the observation that the GSK3aKI mice show no
change in input/output ratio but decreased paired pulse ratio
could be explained by a homeostatic increase in release proba-
bility, compensating for chronic postsynaptic depression.
What is clear is that the dynamic nature of GSK3a rather
than GSK3b is essential for bidirectional synaptic plasticity in
the Schaffer collateral to CA1 synapse. This opens up the possi-
bility that GSK3a could be targeted in neurodegenerative and
cognitive disorders such as Alzheimer’s disease, without the side
FIGURE 2. Long-term potentiation (LTP). (a) Representative
fEPSP traces (average of 6; sampled at times indicated by ^ in b).
(b) fEPSP slope before and after LTP induction (averaged over 1
min for first 5 min following LTP; remainder averaged over 2
min): WT 18(10) slices(animals); GSK3aKI: 7(6), GSK3bKI:
15(6). Arrow: tetanic stimulus. Inset: mean of last 10 min. There
was a significant difference between genotypes, (41–50 min,
F(2,36)5 7.4, P5 0.002): post hoc comparison (adjusted using
Sidak correction) indicated that GSK3aKI but not GSK3bKI mice
differed significantly from WT mice (line shows between-genotype
differences, asterisks above genotype indicate baseline vs last 10
min). ***P< 0.001, *P< 0.05. (Data are mean6 SEM).
FIGURE 3. Long-term depression (LTD). (a) Representative
fEPSP traces (average of 6; sampled at times indicated by ^ in b).
(b) fEPSP slope before and after LTD induction (averaged over 1
min for first 5 min following LTD; remainder averaged over 2
min): WT: data from 32(12) slices (animals); GSK3aKI: 11(5),
GSK3bKI: 33(8). Black bar: low-frequency stimulation. Inset:
mean of last 10 min. There was a significant difference between
genotypes (56–65 min, F(2,73)5 7.3, P< 0.001): post hoc com-
parison (adjusted using Sidak correction) indicated that GSK3aKI
but not GSK3bKI mice differed significantly from WT mice (line
shows between-genotype differences, asterisks above genotype indi-
cate baseline vs last 10 min). ***P< 0.001, **P< 0.01, *P< 0.05.
(Data are mean6 SEM).
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effects that manipulating the ubiquitous GSK3b would inevita-
bly incur.
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